Rapid7 (RPD) Q2 2026 Earnings Call Transcript

Rapid7 reported Q2 FY26 total ARR of $824M (down 2% YoY) and revenue of $210.9M (-1.5% YoY) as noncore product attrition pressured recurring growth, but it exceeded guided profitability with non-GAAP operating income of $28.9M and non-GAAP gross margin of 71.7% (down 215 bps YoY). The company announced a 12% headcount reduction and expects non-GAAP operating margin of ~20% in Q4, while guiding FY26 revenue to $837M–$841M (-~2% at the midpoint) and free cash flow to ~ $130M. Management plans to use $702.6M cash to repay $600M convertible notes due March 2027 and highlighted AI/agentic SOC progress (25% reduction in false-positive queue times) alongside GovRAMP authorization expansion.

Analysis

This is a margin-first reset, not a clean growth inflection. Over the next 1-3 quarters, the stock will trade on whether the core platform can hold flat while noncore attrition slows; if not, the market will likely treat the 20% Q4 margin target as defensive cost cutting rather than evidence of durable franchise improvement. That usually supports downside protection but not a high multiple, because investors need visible ARR stabilization before paying up for operating leverage.

The balance-sheet overhang is meaningfully reduced: cash and FCF appear sufficient to retire the 2027 convert, which lowers tail risk and should cap credit-driven downside. But that also means 2027 earnings quality will be less flattered by interest income, so the market should not extrapolate 2026 free cash flow as the new run-rate. The real second-order winner may be specialized vulnerability-management and adjacent security vendors that benefit if Rapid7 de-prioritizes noncore offerings; the risk is that sales, support, or product coverage shrink faster than management admits, slowing win rates just as the company tries to reaccelerate.

Contrarian view: consensus may be over-optimistic on the speed of a turnaround and under-optimistic on the durability of the floor. The base case here is not a broad re-rating; it is stabilization plus cleaner margins. The thesis is falsified if core ARR does not improve sequentially into Q4 or if gross margin/operating leverage fails to expand despite the headcount reduction, which would imply the company is buying profitability with future revenue capacity.

Key Decisions for Investors

• Fade any post-earnings rally in RPD over the next 2-6 weeks; the setup is better for a short-term trade against the stock once the initial margin relief is priced in, with a stop if core ARR shows two consecutive quarters of sequential stabilization.
• Pair trade: long CRWD or PANW vs short RPD for a 3-6 month horizon. The long leg has durable growth and stronger platform credibility; the short leg is a cleaner way to express skepticism that Rapid7 can convert restructuring into reacceleration.
• Do not add outright long RPD until Q4/Q1 data shows core ARR inflection and gross margin re-expansion without deterioration in pipeline conversion. If that happens, re-underwrite as a turnaround; until then, treat it as a watchlist name, not a conviction long.
• Monitor the March 2027 convert as a catalyst over the next 6-12 months: if management must preserve cash or refinance instead of retiring it outright, the equity story weakens materially. A successful payoff should remove the debt overhang but is already partially telegraphed.
• Watch pure-play vulnerability management peers for relative strength if Rapid7 keeps deemphasizing noncore. Any sustained outperformance there would support the view that RPD is ceding low-priority product share rather than merely rationalizing the portfolio.